Eledon Pharmaceuticals
ELDN
49 hedge funds and large institutions have $32.1M invested in Eledon Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 18 increasing their positions, 12 reducing their positions, and 11 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 12
8% less funds holding
Funds holding: 53 → 49 (-4)
30% less capital invested
Capital invested by funds: $46M → $32.1M (-$13.9M)
36% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$4.92M |
| 2 |
SAM
Senzar Asset Management
New York
|
+$3.86M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$388K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$302K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$187K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
-$3.46M |
| 2 |
GOCM
Green Owl Capital Management
New York
|
-$1.16M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$989K |
| 4 |
KCM
Kingdon Capital Management
New York
|
-$767K |
| 5 |
OPPM
Opus Point Partners Management
New York
|
-$541K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
KCM
51
Kingdon Capital Management
New York
| – | -$767K | -543 | Closed |
|
|
OPPM
52
Opus Point Partners Management
New York
| – | -$541K | -383 | Closed |
|
|
ARTA
53
A.R.T. Advisors
New York
| – | -$239K | -170 | Closed |
|
|
CS
54
Credit Suisse
Zurich,
Switzerland
| – | -$175K | -124 | Closed |
|
55
D.E. Shaw & Co
New York
| – | -$158K | -112 | Closed |
|
56
BNP Paribas Financial Markets
Paris,
France
| – | -$22.3K | -16 | Closed |
|
|
CG
57
Colony Group
Boston,
Massachusetts
| – | -$17K | -12 | Closed |
|
58
UBS Group
Zurich,
Switzerland
| – | -$11K | -8 | Closed |
|
|
TRCT
59
Tower Research Capital (TRC)
New York
| – | -$6.87K | -7 | Closed |
|
|
IA
60
IFP Advisors
Tampa,
Florida
| – | -$2K | -2 | Closed |
|
ELDN Hedge Fund Activity: Q1 2016 in Review
49 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q1 2016, worth a combined $32.1M — down 30% from $46M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of ELDN and 7 opened new positions — a net loss of 4 holders — while 12 trimmed existing stakes and 18 added.
The largest buyer was Sabby Management, opening a new position worth an estimated $4.92M. The largest seller was Bank of New York Mellon, cutting an estimated $3.46M.
- 49 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q1 2016, down from 53 in Q4 2015.
- Funds reported $32.1M of Eledon Pharmaceuticals stock for Q1 2016, down 30% quarter-over-quarter.
- 7 funds opened new Eledon Pharmaceuticals positions in Q1 2016 and 11 closed out, a net change of -4 holders.
- The largest Eledon Pharmaceuticals buyer in Q1 2016 was Sabby Management, an estimated $4.92M added.
- The largest Eledon Pharmaceuticals seller in Q1 2016 was Bank of New York Mellon, an estimated $3.46M sold.
Based on aggregated 13F filings for Q1 2016.